Article Figures & Data
Figures
- FIGURE 1.
Selected fused 124I PET/CT transverse (A) and coronal (B) views of lungs. Views depicted extend from base of diaphragm to vertex of skull.
- FIGURE 2.
Representative coronal slices of absorbed dose (D) maps of 2 different datasets: torso (measured) (A) and head (modeled) (B). In modeled calculation, average tumor activity concentration was placed in 2 tumor-associated VOIs defined using CT; voxels representing normal brain were assigned average (background) brain activity concentration. 3D-RD was then executed using these 2 as source regions of uniform activity irradiating normal brain. In this way, possible calculation artifacts associated with high tumor count–density gradients were avoided. Both images are viewed anteriorly.
Tables
- TABLE 1
3D-RD Absorbed Dose (D), BED, and EUD Results for Different Tumors and for Normal Lung Tissue
Normal lung Tumor Category Lung L brain R brain Sternum Thyroid D — — 986 142 30.6 33.5 BED — — 1270 149 30.8 34.8 Dvox 20.2 42.1 834 132 27.9 41.0 BEDvox 23.1 43.2 1220 142 28.1 42.8 EUD 21.2 23.0 89.1 55.9 10.4 9.0 Vox subscript indicates average voxelized results, whereas absence of subscript refers to results of VOI considered as whole; consequently, there are no results for segmented VOI lung tissues (normal lung vs. lung tumor) as they do not exist separately but form single lung VOI.
- TABLE 2
Recommended Administered Activities for Estimated 27 Gy to Lung VOI as Determined by Different Methodologies
Administered activities (GBq) Method 3D-RD S value (OLINDA) Benua–Leeper Prospective 5.11 3.14 8.17 Retrospective 5.11 5.16 5.17 Retrospective S-value method used lung mass rather than body mass as parameter; retrospective Benua–Leeper calculation followed DRC methodology (7).
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- MIRD Pamphlet No. 28, Part 1: MIRDcalc--A Software Tool for Medical Internal Radiation Dosimetry
- Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
- Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer
- Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates
- Assessment of Lesion Response in the Initial Radioiodine Treatment of Differentiated Thyroid Cancer Using 124I PET Imaging
- Three-Dimensional Personalized Monte Carlo Dosimetry in 90Y Resin Microspheres Therapy of Hepatic Metastases: Nontumoral Liver and Lungs Radiation Protection Considerations and Treatment Planning Optimization
- Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging
- Radiobiologic Optimization of Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin Lymphoma
- Study of the Impact of Tissue Density Heterogeneities on 3-Dimensional Abdominal Dosimetry: Comparison Between Dose Kernel Convolution and Direct Monte Carlo Methods
- MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy
- Fine-Resolution Voxel S Values for Constructing Absorbed Dose Distributions at Variable Voxel Size
- Dosimetry and thyroid cancer: the individual dosage of radioiodine
- Arterial Wall Dosimetry for Non-Hodgkin Lymphoma Patients Treated with Radioimmunotherapy